Health care stocks were mixed premarket Friday, with the Health Care Select Sector SPDR Fund (XLV) slightly lower and the iShares Biotechnology ETF (IBB) up 0.3%.

Biogen (BIIB) and Eisai said a new drug application has been filed in Japan for a subcutaneous autoinjector formulation of Leqembi, or lecanemab, to treat people with early Alzheimer's disease. Biogen shares were 0.5% lower pre-bell.

Vanda Pharmaceuticals (VNDA) stock was down more than 1% after the company said it has agreed to an extension of the US Food and Drug Administration review of the partial clinical hold on long-term clinical studies of tradipitant to treat motion sickness.

Protagenic Therapeutics (PTIX) shares were down 9% after the company said it received a Nasdaq notice for failing to meet the minimum $2.5 million stockholders' equity requirement and for not filing its quarterly report on time.